PHVS - Pharvaris BV
Pharvaris BV Logo

PHVS - Pharvaris BV

https://pharvaris.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - Pharvaris ( NASDAQ:PHVS )
Benzinga • 1 month, 3 weeks ago • score: 0.14
ZUG, Switzerland, July 24, 2025 ( GLOBE NEWSWIRE ) -- Pharvaris N.V. ( ( "Pharvaris, NASDAQ:PHVS ) , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary ...
Neutral
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
GlobeNewswire • 2 months, 2 weeks ago • score: 0.13
ZUG, Switzerland, June 27, 2025 ( GLOBE NEWSWIRE ) -- Pharvaris ( Nasdaq: PHVS ) , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema ( HAE ) ...
Neutral
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - Pharvaris ( NASDAQ:PHVS )
Benzinga • 2 months, 2 weeks ago • score: 0.11
ZUG, Switzerland, June 27, 2025 ( GLOBE NEWSWIRE ) -- Pharvaris PHVS, a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema ( HAE ) and acquired ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the Netherlands.

52W High
$26.33
52W Low
$11.51
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
-2.80
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.38
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
6.90
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
5.32%
Institutions (25–75% balanced)
76.35%
Shares Outstanding
64,300,000
Float
37,106,200
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-3.60
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.65%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.5248
Previous
0.5361
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025